PepsiCo Beats Estimates; Hallador Wins $700M Contracts; Haemonetics Jumps 17.88%; DarkIris Plunges 60.26% on Financing

Mumbai, 8 October 2026: U.S. stock market trading on Thursday featured notable moves across companies as investors responded to earnings results, business agreements, financing announcements and corporate actions. Shares of Hallador Energy, Haemonetics and Byrna advanced, while Resources Connection, DarkIris and AngioDynamics recorded sharp declines.

Several companies also reported major developments, including new power contracts, financing arrangements, acquisitions and changes to their financial outlooks, highlighting a busy session for individual stocks.

PepsiCo Q3 Earnings Beat Estimates, But Lower Outlook Limits Gain; Shares Rise 1.48%

PepsiCo reported better-than-expected fiscal third-quarter 2026 results on Thursday, with adjusted earnings of $2.34 per share beating the $2.30 analyst estimate. Revenue rose to $25.27 billion, above the $24.97 billion forecast.

Organic revenue growth accelerated to 3.1%, its strongest pace since the fourth quarter of 2023. International operations remained a key growth driver, with organic revenue increasing 8% and operating margin expanding by 105 basis points.

However, PepsiCo lowered its near-term earnings outlook as higher input costs, unfavorable product mix and the loss of a tariff benefit pressured margins. Management said the guidance cut reflected profitability challenges rather than weaker demand.

PepsiCo shares have risen during Thursday’s session as investors weigh the earnings beat against the cautious outlook. The stock opened at $124.30, compared with the previous close of $123.73. It has traded between a session low of $124.05 and a high of $126.75 so far.

At around $125.44, shares were up 1.48%, or $1.71, from the previous close. The stock has also remained above its opening price, indicating that investors have so far responded positively to the stronger quarterly performance.

Still, the limited gain suggests caution over PepsiCo’s margin outlook. North American snacks showed improvement after a price reset, while the North American beverage business remained weaker. The company expects fourth-quarter organic revenue to improve sequentially but continues to face cost and margin pressures.

Resources Connection Q1 Revenue Falls 18.5%, Adjusted EBITDA Loss Widens; Shares Fall 20.6%

Resources Connection reported fiscal first-quarter 2027 revenue of $98.1 million, down 18.5% year over year. The company reported an adjusted EBITDA loss of $3.6 million, while gross margin declined to 37.4% from 39.5% in the prior-year quarter.

Revenue declined across several business segments. On-Demand Talent revenue fell 13.2% to $38.6 million, while Consulting revenue declined 25.8% to $32.4 million. Consulting billable hours fell 27.1%, partly offset by a 2.2% increase in the average bill rate. Outsourced Services revenue increased 0.2% to $10 million.

Resources Connection said North American pipeline creation increased sequentially during the quarter, including growth in the Consulting pipeline. However, closed-won business and project starts remained below the level needed to offset completed projects and seasonal factors.

The company reduced run-rate SG&A by 9.4% to $40.3 million. It ended the quarter with $61.2 million in cash and cash equivalents and no outstanding debt.

For the second quarter, Resources Connection expects revenue of $95 million to $100 million, gross margin of 36% to 37%, and run-rate SG&A of $40 million to $42 million.

RGP shares opened at $3.06, reached an intraday high of $3.34 and a low of $2.88. At around $2.97, the stock was down 20.59% from the previous close of approximately $3.74. The stock traded near its 52-week low of $2.88 during the session.

Also Read: What Is the New York Stock Exchange (NYSE)?

Haemonetics Shares Rise 17.88% as CSL Plans 2027 Rollout of Plasma Devices

Haemonetics shares rose 17.88% after CSL Plasma said it expects to complete the rollout of Haemonetics’ NexSys PCS devices with Persona PLUS technology and related disposables across its U.S. plasma collection centers by the end of 2027.

The companies entered a non-exclusive supply agreement in August 2026, under which CSL may use Haemonetics’ devices and purchase related disposables in the United States. CSL said it currently anticipates the transition will cover all of its U.S. plasma collection centers.

Haemonetics shares opened at $115.00, reached an intraday high of $121.00 and a low of $111.66. The stock was quoted at $119.71, up 17.88% from the previous close of approximately $101.51.

Haemonetics said the scope and timing of the rollout remain subject to change under the supply agreement, while implementation details are still being determined. The company also said it is not updating its fiscal 2027 guidance at this time.

Haemonetics expects to provide an update on the anticipated financial impact of the supply agreement during its second-quarter fiscal 2027 earnings call in November 2026. CSL shares were down 0.29% during the session.

Levi Strauss Q3 Revenue Rises 4%, Raises FY2026 EPS Outlook; Shares Fall 4.5%

Levi Strauss & Co. reported third-quarter fiscal 2026 net revenue of $1.61 billion, up 4% from $1.54 billion a year earlier and up 5% on an organic basis. The company also raised its full-year 2026 margin and earnings outlook.

Operating margin increased to 13.8% from 10.8%, while adjusted EBIT margin rose to 15.5% from 11.8%. Gross margin expanded to 66.2% from 61.7%. Net income from continuing operations increased to $169 million from $122 million, while adjusted net income reached $189 million, up 39%.

Diluted EPS from continuing operations increased to $0.43 from $0.31. Adjusted diluted EPS rose to $0.48 from $0.34. Levi Strauss said wholesale revenue increased 6%, while direct-to-consumer revenue rose 2%. E-commerce revenue increased 10%.

For fiscal 2026, the company raised its adjusted EBIT margin outlook to approximately 12.1%, from the previous 12%, and increased adjusted diluted EPS guidance to $1.54-$1.56 from $1.46-$1.52. It expects organic revenue growth of approximately 6%.

Levi Strauss also plans a $100 million accelerated share repurchase program and declared a quarterly dividend of $0.16 per share.

Levi Strauss shares opened at $19.00 on October 8, reached an intraday high of $19.39 and a low of $18.58. At around $18.82, LEVI was down 4.5% from the previous close of approximately $19.71. The stock remained below its previous close during the session.

Applied Digital Q1 FY2027 Revenue Jumps 322%; Shares Trade 9.92% Higher

Applied Digital reported fiscal first-quarter 2027 results that exceeded Wall Street estimates, with revenue reaching $341.9 million, compared with the $111.19 million consensus forecast. Adjusted loss came to $0.01 per share, versus the expected $0.27 loss per share.

Revenue increased 322% year over year from $80.9 million, driven largely by growth in high-performance computing hosting. The business generated $262.6 million in revenue during the quarter. Adjusted EBITDA increased to $64.4 million from $500,000 a year earlier.

Applied Digital reported an adjusted net loss of $4.1 million, while its net loss from continuing operations was $221 million, or $0.76 per share. The company ended the quarter with $2.9 billion in cash and cash equivalents and $700 million in restricted cash.

The company said it has approximately $36 billion in contracted revenue across five campuses. Management also said demand for AI infrastructure remains strong, with much of its 2027 capacity already contracted.

Applied Digital shares closed the regular session at $23.81, down 6.04% from the previous close of $25.34. The stock opened the current session at $24.35, reached a high of $24.43 and a low of $22.62. At around $22.83, APLD was down 4.12% from the previous close.

The company also highlighted a $1.59 billion financing completed during the quarter through 7% senior secured notes due 2031.

Also Read: How to invest in US stocks

Helen of Troy Q2 EPS Beats Estimates by 55%; Shares Jump 7.24% as Margins and Cash Flow Improve

Helen of Troy reported fiscal second-quarter 2027 adjusted earnings of $0.79 per share, beating Wall Street’s $0.51 estimate by $0.28, or 54.9%. Revenue came in at $440.9 million, slightly below the $443.2 million forecast, a miss of about 0.5%. The stronger-than-expected profit, wider margins and improved cash-flow outlook drove a sharp positive response in the stock.

Helen of Troy shares opened at $31.33 on Thursday, compared with the previous close of $25.55, and climbed to a session high of $31.98. The stock touched a low of $26.52 during the session.

At around $27.40, HELE was up 7.24%, or $1.85, from the previous close. The shares initially surged after the results, reaching nearly $32 before giving back some gains. The stock remains close to its 52-week high of $31.98.

The company’s gross margin expanded 800 basis points to 52.2%, helped by tariff refunds and lower trade spending. Adjusted EBITDA also increased by $13.2 million from a year earlier.

Helen of Troy raised its free cash flow guidance to $120 million-$140 million and said debt reduction was ahead of schedule. Debt fell $221 million year over year to $673 million, while net leverage declined to 3.0x.

Home & Outdoor sales increased 9.2%, led by OXO and Osprey, while Beauty & Wellness sales fell 4.5%. Management maintained its base-business EBITDA outlook and said it remains focused on brand investment, cost discipline and further debt reduction.

Byrna Q3 Revenue Misses Estimates by 41%, but Shares Rebound 11.36% as Margins Improve

Byrna Technologies reported a sharp decline in fiscal third-quarter revenue and a wider-than-expected loss, with revenue falling 46% year over year to $15.3 million from $28.2 million. Revenue missed Wall Street’s $25.99 million estimate by $10.69 million, or 41.1%. The company also reported a loss of $0.13 per share, wider than the expected $0.04 loss.

Despite the weak results, Byrna shares have moved higher during Thursday’s session. The stock opened at $3.68, compared with the previous close of $4.05, and initially fell to a session low of $3.50. It later rebounded sharply, reaching a high of $4.53.

At around $4.51, BYRN was up 11.36%, or $0.46, from the previous close. The rebound represents a significant turnaround from the early-session weakness and suggests investors have focused on the company’s improving profitability alongside the revenue miss.

Byrna’s adjusted gross margin rose to about 65%, compared with 62% in the previous quarter and roughly 60% a year earlier. The company said outsourcing ammunition production generated an approximately 1,200-basis-point margin benefit in that category.

Management also highlighted its $9.4 million cash and marketable securities position and zero debt, while pointing to new retail initiatives, marketing changes and the Hero Defense Systems acquisition as potential growth drivers for 2027.

The sharp stock rebound indicates that investors may view the margin improvements and planned growth initiatives as important offsets to the severe revenue weakness.

Tilray Q1 Revenue Hits Record $257.1M, but Shares Fall 5.48% on Continued Losses

Tilray Brands reported record fiscal first-quarter 2027 revenue of $257.1 million, up 23% from $209.5 million a year earlier, while gross profit rose 35% to $77.5 million. However, the company remained unprofitable, reporting a $40 million net loss, compared with net income of $1.5 million a year earlier.

Gross margin improved to 30%, up about 300 basis points year over year, while adjusted net loss narrowed to about $3 million. Adjusted EBITDA came in at $9.2 million, slightly below $10.2 million a year earlier. Tilray also ended the quarter with about $221 million in cash, restricted cash and marketable securities.

Despite the record revenue, investors sold the stock. Tilray shares opened at $3.49, compared with the previous close of $3.715, and traded between a session low of $3.38 and a high of $3.62.

At around $3.51, TLRY was down 5.48%, or $0.20, from the previous close. The decline indicates that investors have focused on the continued net loss and slightly weaker adjusted EBITDA rather than the stronger revenue and margin performance.

Beverage revenue jumped 82% to $101.5 million, helped by BrewDog, which reached profitability during the quarter. Tilray also reaffirmed fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million and said it remains focused on debt reduction and international cannabis growth.

The stock remains close to its 52-week low of $3.38, underscoring continued investor caution despite the company’s improving operating metrics.

AngioDynamics Q1 Loss Beats Estimates by 64%, but Shares Fall 19.38%

AngioDynamics reported a narrower-than-expected fiscal first-quarter 2027 loss, with adjusted EPS at -$0.04, compared with the expected -$0.11. Revenue rose 6.9% to $80.9 million, slightly above the $80.5 million forecast. Despite the earnings beat, investors sold the stock as concerns over the full-year outlook and cash use weighed on sentiment.

AngioDynamics shares opened at $13.22, compared with the previous close of $14.19, and traded between a session low of $11.06 and a high of $13.80.

At around $11.42, ANGO was down 19.38%, or $2.75, from the previous close. The stock fell below its opening price and approached its 52-week low of $9.39, showing that investors have so far reacted negatively despite the quarterly beats.

Gross margin expanded 410 basis points to 59.4%, while adjusted EBITDA more than doubled to $5 million from $2.2 million. Med Tech revenue increased 13.2% to $39.9 million, led by Auryon and AlphaVac, and now represents 49% of total sales.

However, the company kept its fiscal 2027 guidance unchanged, calling for revenue of $336 million-$341 million and adjusted EBITDA of $13 million-$16 million. Management also expects an adjusted loss of $0.29-$0.24 per share for the full year.

Also Read: US Stock Market Timings 

Crescent Energy to Acquire Devon’s Eagle Ford Assets for $3.85B; Shares Fall 4.49%

Crescent Energy has agreed to acquire Eagle Ford assets from Devon Energy for an estimated net purchase price of $3.85 billion. The transaction includes approximately 68,000 barrels of oil equivalent per day of net production and more than 600 locations in the Karnes Trough.

Crescent said the acquisition is expected to close in the fourth quarter of 2026 or early 2027, subject to customary conditions. The company also identified about $140 million in annual synergies from drilling and completion, lease operating expenses and marketing.

Crescent shares opened at $13.20, reached an intraday high of $13.45 and a low of $12.67. The stock was quoted at $12.86, down 4.49% from the previous close of approximately $13.46.

The transaction includes Devon-owned mineral rights, which Crescent plans to integrate into its Crescent Royalties platform. Crescent expects to fund the acquisition using cash on hand and a combination of debt and equity, depending on market conditions.

Devon Energy shares were quoted at $48.98, up 2.29%, during the session. The deal is expected to add to Crescent’s cash flow from operations, free cash flow and net asset value, according to the company.

Copart Extends $10.50 ACV Tender Offer to October 15; Shares Rise 1.47%

Copart announced that its wholly owned subsidiary, Apple Merger Sub, has further extended its all-cash tender offer to acquire all outstanding shares of ACV Auctions for $10.50 per share.

The tender offer, which was previously scheduled to expire on October 7, will now expire at 5:00 p.m. ET on October 15, 2026, unless further extended or terminated earlier. The extension provides additional time for the waiting period under the Hart-Scott-Rodino Act, which is scheduled to expire on October 13.

As of October 7, approximately 90.2 million ACV shares, representing 52.84% of outstanding shares, had been validly tendered and not withdrawn. The transaction remains subject to certain conditions, including the minimum tender condition and expiration or termination of the applicable HSR waiting period.

Copart shares opened at $26.56, reached an intraday high of $27.08 and a low of $26.48. The stock was quoted at $27.02, up 1.47% from the previous close of approximately $26.63.

ACV Auctions shares were up 0.05% during the session. Stockholders who already tendered their shares do not need to retender them following the extension.

TSMC Signs $2B GlobalFoundries Deal, but GFS Shares Fall 0.03% Intraday

Taiwan Semiconductor Manufacturing Co. has signed a $2 billion, multi-year supply agreement with GlobalFoundries to manufacture silicon interposers in the United States. GlobalFoundries will provide manufacturing services from its Malta, New York facility to support TSMC’s Chip-on-Wafer-on-Substrate (CoWoS) advanced packaging ecosystem.

The agreement has an initial five-year term, with production capacity expected to expand as demand increases. GlobalFoundries plans to add fabrication capacity at its New York site, with volume production expected to begin ramping in the first half of 2028.

GlobalFoundries shares opened at $49.24, reached an intraday high of $51.45 and a low of $47.91. The stock was quoted at $48.08, down 0.03% from the previous close of approximately $48.09, after earlier premarket trading showed a gain of about 4%.

The agreement will support TSMC’s CoWoS packaging framework and includes infrastructure for embedded deep trench capacitor components. The companies expect the arrangement to support multiple product generations as production capacity expands.

TSMC shares opened at $466.32, compared with the previous close of $472.20, and traded between $453.63 and $471.12. TSM shares were quoted at $453.16, down 4.03% during the session.

AT&T Partners with OpenAI for AI-Powered Legal Operations; Shares Rise 0.08%

AT&T announced a strategic collaboration with OpenAI on October 8, 2026, to develop an advanced in-house legal department powered by artificial intelligence. The initiative will build on AT&T’s LegalEdge platform and focus on applying AI across legal workflows, institutional knowledge and routine legal tasks.

AT&T said LegalEdge, launched earlier in 2026, had managed nearly 100 cases within six months. The collaboration with OpenAI will further develop the platform and support the company’s legal operations. AT&T said the initiative aims to streamline workflows, improve access to institutional knowledge and allow legal professionals to spend more time on higher-value work.

The partnership adds OpenAI technology to AT&T’s existing legal technology efforts. The companies did not disclose financial terms for the collaboration.

AT&T shares opened at $24.62 on October 8, compared with the previous close of approximately $24.81. The stock traded between an intraday low of $24.50 and a high of $24.84.

At around $24.83, AT&T shares were up 0.08%, or approximately $0.02, from the previous close. The stock remained within a narrow trading range during the session, with a difference of $0.34 between its intraday high and low.

The announcement comes as AT&T continues expanding its use of artificial intelligence across internal business operations. The company’s LegalEdge platform forms part of those efforts, with the latest collaboration focused specifically on its in-house legal department.

Also Read: What Are Fractional Shares? 

Richardson Electronics Q1 Revenue Jumps 19%, EPS Beats Estimates; Shares Fall 0.1%

Richardson Electronics reported fiscal first-quarter 2027 revenue of $64.9 million, up 18.9% year over year, marking its ninth consecutive quarter of year-over-year sales growth. Diluted earnings per share reached $0.27, compared with the Wall Street estimate of $0.10.

Net income more than doubled to $4.1 million from $1.9 million a year earlier, while operating income increased more than fourfold to $5.1 million, representing 7.9% of sales.

Gross margin expanded to 34.6% from 31.0% in the prior-year quarter. Richardson Electronics said the quarter included a 170-basis-point benefit from an IEEPA tariff refund. Excluding that benefit, gross margin was 32.9%.

The company reported growth across its businesses while continuing its focus on power, microwave and imaging solutions. Richardson Electronics is also expanding its presence in battery energy storage systems (BESS) as part of its green energy strategy.

Shares opened at $20.11 on October 8, compared with the previous close of $20.00. The stock reached an intraday high of $20.95 and a low of $19.38.

At around $19.98, RELL was down approximately 0.1% from the previous close. The stock traded within a $1.57 intraday range during the session.

Richardson Electronics serves more than 20,000 OEM and end-user customers through over 60 locations globally and manufactures more than 55% of the products it sells across its primary business areas.

Nvidia-Backed Iambic Therapeutics Targets Up to $806 Million Valuation in US IPO

Iambic Therapeutics, a biotechnology company backed by Nvidia, is seeking to raise up to $159.4 million through a U.S. initial public offering, according to a regulatory filing on October 8, 2026. At the top of its proposed price range, the offering would value the company at approximately $805.8 million.

Iambic plans to offer about 9.38 million shares at a proposed price of $15 to $17 per share. The company expects to list on the Nasdaq under the ticker “IAM” after the offering closes.

Founded in 2019 as Entos, Iambic is developing drug candidates for solid tumors using an artificial intelligence platform. The company is among biotechnology firms continuing to pursue U.S. listings despite a subdued broader IPO market.

Investment firms ARK Investment Management and Duquesne Family Office have indicated interest in purchasing approximately $60 million of shares in the offering, according to the filing.

The IPO comes as new U.S. listings face a market environment marked by higher Treasury yields and stock-market volatility. Biotech companies have continued to attract interest despite these conditions.

J.P. Morgan, Jefferies, BofA Securities and Citigroup are serving as lead underwriters for the offering.

Iambic’s proposed listing also highlights the company’s connection to Nvidia, which has backed the biotechnology firm. The IPO proceeds are expected to support the company as it advances its pipeline of AI-developed drug candidates targeting solid tumors.

The proposed valuation is based on the number of outstanding shares disclosed in the filing and represents a valuation of up to approximately $806 million at the top of the IPO price range.

Wolfspeed Secures $1.5 Billion Defense Department Loan Commitment; Shares Rise 27% in Extended Trading

Wolfspeed said it received a conditional loan commitment of up to $1.5 billion from the U.S. Department of Defense to expand domestic production of silicon carbide materials and power devices. The company announced the commitment on October 7, sending its shares up 27% in extended trading.

The proposed financing carries a 30-year term through the Defense Department’s Office of Strategic Capital. Wolfspeed said it plans to use the financing to upgrade its gallium nitride technology for next-generation communications infrastructure and electronic warfare systems. The company also plans to develop radiation-hardening capabilities.

The funding remains subject to due diligence, definitive agreements, government approvals and other conditions. Under the proposed terms, Wolfspeed would issue warrants to the Defense Department to purchase up to 7.5% of its fully diluted equity.

Wolfspeed produces silicon carbide chips used in applications that require high levels of power conversion, including electric vehicles, solar inverters and industrial power systems.

In regular trading on October 8, Wolfspeed opened at $35.02, reached an intraday high of $35.94 and fell to a low of $29.52. The shares were trading at $30.16 at 2:00 p.m. ET. The stock had moved lower from its opening level during the session after its extended-hours gain following the financing announcement.

DarkIris Prices $6 Million Public Offering at $1.44 Per Unit; Shares Fall 60.26%

DarkIris Inc. priced a $6 million public offering at $1.44 per unit, according to a company announcement on October 8. The best-efforts offering includes 4,166,666 units, with each unit containing one Class A ordinary share and one warrant to purchase another Class A ordinary share.

The company is also offering pre-funded units priced at $1.4399 each. The warrants have an exercise price of $2.04 per Class A ordinary share and become immediately exercisable upon issuance. They expire six months after issuance. The warrants also include a zero-cash exercise option that allows holders to exchange each warrant for approximately 12 Class A ordinary shares that would otherwise be issuable through a cash exercise.

DarkIris expects the offering to close on or about Friday, subject to customary closing conditions. The company said it plans to use the net proceeds for working capital and general corporate purposes. Prime Number Capital is serving as the sole placement agent.

In regular trading on October 8, DarkIris opened at $1.37, reached a high of $1.47 and fell to a low of $0.64. The shares were trading at $0.66 at 2:01 p.m. ET, down 60.26%. The current price was also below the offering price of $1.44 per unit. The company’s securities are being offered under registration statements filed with the U.S. Securities and Exchange Commission.

Also Read: What Is the S&P 500? A Simple Guide for Everyday Investors

Blue Star Foods Enacts 1-for-1,600 Reverse Split; NN Inc. Redeems $35.7 Million Preferred Stock

Blue Star Foods Corp. enacted a 1-for-1,600 reverse stock split at 12:01 a.m. Eastern Time on October 8, 2026. Under the split, every 1,600 shares outstanding immediately before the effective time were combined into one share. The company expects its common stock to trade on a split-adjusted basis in the over-the-counter market.

Blue Star Foods reported 171.98 million pre-split shares outstanding, with approximately 107,488 shares expected after the reverse split following fractional-share treatment. The transaction does not change the common stock’s $0.0001 par value or the company’s 5.005 billion authorized shares. Outstanding options, warrants, convertible securities and equity awards are subject to proportional adjustments under their respective terms.

Separately, NN Inc. completed the redemption of all 18,400 outstanding Series D Perpetual Preferred Stock shares for approximately $30.7 million. The preferred stock had a stated value of $35.7 million, with the transaction including a $5 million incentive from its sole holder.

NN Inc. funded the redemption using proceeds from a $53.1 million private placement completed October 5. No Series D shares remain outstanding.

NNBR opened at $3.96, reached $4.00, fell to $3.88, and traded at $3.96 at 2:10 p.m. ET, down 1.37%.

Hallador Energy Secures $700 Million Power Agreements; Shares Rise 9.27%

Hallador Energy Company announced approximately $700 million in new electricity capacity and energy supply agreements, increasing its total forward sales book to about $3 billion. The six-year agreements were signed with an investment-grade utility operating in MISO Zone 6 and cover electricity capacity and energy from Hallador’s Merom Generating Station.

Deliveries under the agreements are scheduled to begin on June 1, 2029, and continue through May 31, 2035. The capacity agreement covers an annual average of 225 megawatts (MW) and is expected to generate about $271 million in revenue. The accompanying energy agreement covers an average annual base quantity of 200 MW and is expected to generate about $422 million based on current forward electricity prices.

Hallador said the new contracts represent its third announced capacity agreement of 2026, with the latest capacity contract priced more than 20% above the agreement announced in March. The company now has about 95% of Merom’s accredited generating capacity contracted through 2035.

Separately, Hallador submitted an air permit application on September 25 for its proposed 460 MW Turtle Creek natural gas facility, which would be located next to Merom.

In trading on October 8, Hallador shares opened at $14.76, reached a high of $15.39 and a low of $14.50. The stock was at $14.92 at 2:13 p.m. ET, up 9.27%. U.S. stocks saw mixed company-specific moves as earnings, new contracts, financing deals and corporate actions drove sharp gains and declines. Hallador Energy, Haemonetics and Byrna advanced, while Resources Connection, DarkIris and AngioDynamics fell. The varied reactions reflected a session marked by significant moves across multiple sectors and individual stocks.